ECSP034765A - Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocina - Google Patents
Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocinaInfo
- Publication number
- ECSP034765A ECSP034765A EC2003004765A ECSP034765A ECSP034765A EC SP034765 A ECSP034765 A EC SP034765A EC 2003004765 A EC2003004765 A EC 2003004765A EC SP034765 A ECSP034765 A EC SP034765A EC SP034765 A ECSP034765 A EC SP034765A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- derivatives
- chemiokin
- bipiperidinyl
- receptors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0108876.4A GB0108876D0 (en) | 2001-04-09 | 2001-04-09 | Organic Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034765A true ECSP034765A (es) | 2003-10-28 |
Family
ID=9912541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004765A ECSP034765A (es) | 2001-04-09 | 2003-09-11 | Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocina |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040142920A1 (enExample) |
| EP (1) | EP1379504B1 (enExample) |
| JP (1) | JP4366079B2 (enExample) |
| KR (1) | KR100616039B1 (enExample) |
| CN (1) | CN100469767C (enExample) |
| AR (1) | AR035815A1 (enExample) |
| AT (1) | ATE446950T1 (enExample) |
| AU (1) | AU2002302511B2 (enExample) |
| BR (1) | BR0208741A (enExample) |
| CA (1) | CA2439241C (enExample) |
| CZ (1) | CZ20032723A3 (enExample) |
| DE (1) | DE60234167D1 (enExample) |
| EC (1) | ECSP034765A (enExample) |
| ES (1) | ES2335393T3 (enExample) |
| GB (1) | GB0108876D0 (enExample) |
| HU (1) | HUP0303724A3 (enExample) |
| IL (1) | IL157428A0 (enExample) |
| MX (1) | MXPA03009220A (enExample) |
| NO (1) | NO20034324D0 (enExample) |
| NZ (1) | NZ528712A (enExample) |
| PE (1) | PE20021004A1 (enExample) |
| PL (1) | PL363011A1 (enExample) |
| PT (1) | PT1379504E (enExample) |
| RU (1) | RU2296751C2 (enExample) |
| SK (1) | SK12422003A3 (enExample) |
| WO (1) | WO2002081449A1 (enExample) |
| ZA (1) | ZA200306432B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1404667T3 (da) | 2001-07-02 | 2006-07-10 | Astrazeneca Ab | Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AR036366A1 (es) | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| ATE334680T1 (de) * | 2002-10-04 | 2006-08-15 | Ucb Sa | 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel |
| GB0223223D0 (en) | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
| DE60324014D1 (de) * | 2002-12-13 | 2008-11-20 | Smithkline Beecham Corp | Heterocyclische verbindungen alsccr5-antagonisten |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| EP1616862A4 (en) * | 2003-04-18 | 2008-07-16 | Ono Pharmaceutical Co | HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| WO2004113323A1 (en) * | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
| CA2544377A1 (en) * | 2003-11-03 | 2005-05-12 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
| US7230022B2 (en) | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| US7288563B2 (en) | 2004-02-19 | 2007-10-30 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| WO2006077499A1 (en) * | 2005-01-20 | 2006-07-27 | Pfizer Limited | Chemical compounds |
| KR20080037655A (ko) | 2005-07-21 | 2008-04-30 | 아스트라제네카 아베 | 신규 피페리딘 유도체 |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| JP2010512340A (ja) * | 2006-12-06 | 2010-04-22 | ジェンザイム・コーポレーション | ケモカイン受容体結合性化合物 |
| US8410144B2 (en) | 2009-03-31 | 2013-04-02 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| EP3597761B1 (en) | 2011-03-09 | 2025-05-07 | Richard G. Pestell | Prostate cancer cell lines, gene signatures and uses thereof |
| EP2861302A4 (en) * | 2012-05-14 | 2016-08-24 | Prostagene Llc | USE OF CCR5 MODULATORS IN THE TREATMENT OF CANCER |
| JP2017503783A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体アルファ２ｃ拮抗薬としての置換されたビピペリジニル誘導体 |
| JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
| JP2017503778A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体α２Ｃ拮抗薬としての置換されたビピペリジニル誘導体 |
| EP3083593A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte piperidinyl-tetrahydrochinoline |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US5952349A (en) * | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| ES2314305T3 (es) * | 1996-09-10 | 2009-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion. |
| DE19637043A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien |
| DE19643331A1 (de) * | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP1175402B1 (en) * | 1999-05-04 | 2005-07-20 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| ES2274793T3 (es) * | 1999-06-11 | 2007-06-01 | MERCK & CO., INC. | Modulares n-ciclopentilicos de la actividad del receptor de la quimioquina. |
| CA2413418A1 (en) * | 2000-06-21 | 2001-12-27 | Joseph B. Santella | Piperidine amides as modulators of chemokine receptor activity |
| EP1322628A2 (en) * | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
| AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0223223D0 (en) * | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
-
2001
- 2001-04-09 GB GBGB0108876.4A patent/GB0108876D0/en not_active Ceased
-
2002
- 2002-04-05 AR ARP020101270A patent/AR035815A1/es not_active Application Discontinuation
- 2002-04-08 EP EP02730122A patent/EP1379504B1/en not_active Expired - Lifetime
- 2002-04-08 DE DE60234167T patent/DE60234167D1/de not_active Expired - Lifetime
- 2002-04-08 HU HU0303724A patent/HUP0303724A3/hu unknown
- 2002-04-08 NZ NZ528712A patent/NZ528712A/en unknown
- 2002-04-08 WO PCT/EP2002/003871 patent/WO2002081449A1/en not_active Ceased
- 2002-04-08 PT PT02730122T patent/PT1379504E/pt unknown
- 2002-04-08 PE PE2002000282A patent/PE20021004A1/es not_active Application Discontinuation
- 2002-04-08 CA CA2439241A patent/CA2439241C/en not_active Expired - Fee Related
- 2002-04-08 BR BR0208741-3A patent/BR0208741A/pt not_active IP Right Cessation
- 2002-04-08 ES ES02730122T patent/ES2335393T3/es not_active Expired - Lifetime
- 2002-04-08 PL PL02363011A patent/PL363011A1/xx not_active Application Discontinuation
- 2002-04-08 JP JP2002579437A patent/JP4366079B2/ja not_active Expired - Fee Related
- 2002-04-08 KR KR1020037013161A patent/KR100616039B1/ko not_active Expired - Fee Related
- 2002-04-08 AU AU2002302511A patent/AU2002302511B2/en not_active Ceased
- 2002-04-08 SK SK1242-2003A patent/SK12422003A3/sk not_active Application Discontinuation
- 2002-04-08 RU RU2003130642/04A patent/RU2296751C2/ru not_active IP Right Cessation
- 2002-04-08 AT AT02730122T patent/ATE446950T1/de not_active IP Right Cessation
- 2002-04-08 IL IL15742802A patent/IL157428A0/xx unknown
- 2002-04-08 CN CNB028079507A patent/CN100469767C/zh not_active Expired - Fee Related
- 2002-04-08 US US10/472,653 patent/US20040142920A1/en not_active Abandoned
- 2002-04-08 CZ CZ20032723A patent/CZ20032723A3/cs unknown
- 2002-04-08 MX MXPA03009220A patent/MXPA03009220A/es active IP Right Grant
-
2003
- 2003-08-19 ZA ZA200306432A patent/ZA200306432B/en unknown
- 2003-09-11 EC EC2003004765A patent/ECSP034765A/es unknown
- 2003-09-26 NO NO20034324A patent/NO20034324D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034765A (es) | Derivados de bipiperidinilo y su uso como inhibidores de receptores de quimiocina | |
| NO20015365D0 (no) | Piperidinderivater som er anvendbare som CCR5-antagonister | |
| NO20015366D0 (no) | Piperazinderivater som er anvendbare som CCR5-antagonister | |
| UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
| DK1526134T3 (da) | Triazolyltropanderivater som CCR5-modulatorer | |
| NO20041266L (no) | Piperidinderivater som kan anvendes som CCR5-antagonister | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| NO20031672L (no) | Aza- og polyazanaftalenylkarboksamid-derivater anvendbare som HIV-integraseinhibitorer | |
| NO20021450L (no) | Cykliske aminforbindelser som CCR5-antagonister | |
| UY28623A1 (es) | Derivados de pirazol y usos de los mismos | |
| ES2195785B1 (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
| EE200300054A (et) | Kinaasi inhibiitoritena toimivad bitsüklopürasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid | |
| ECSP034859A (es) | Nuevos derivados de pirrol como agentes farmacéuticos | |
| ECSP088971A (es) | Ligandos 101 de los receptores nicotínicos de acetilcolina | |
| HN2002000300A (es) | Nuevos derivados de piperazina | |
| BRPI0413094A (pt) | derivados de quinolina e seu uso em terapia | |
| DK1581518T3 (da) | Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister | |
| HN2001000280A (es) | Derivados de piperidina como antagonstas selectivos de subtipo de n - metil - d - aspartato. | |
| HN2001000235A (es) | Derivados puentes de piperazina | |
| NO20063393L (no) | Farmasoytiske preparater | |
| ATE418542T1 (de) | Als ccr5-antagonisten verwendbare aryloxim- piperazine | |
| ATE301463T1 (de) | Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist | |
| SE0300457D0 (sv) | Novel compounds | |
| PT1497292E (pt) | Derivados de azaindolilpiperidina como agentes anti-histaminicos e antialergicos | |
| NO20065898L (no) | 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner |